scholarly journals Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary

2019 ◽  
Vol 46 (7) ◽  
pp. 751-754 ◽  
Author(s):  
Kim A. Papp ◽  
Boulos Haraoui ◽  
Deepali Kumar ◽  
John K. Marshall ◽  
Robert Bissonnette ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Patient Population ◽  
Elevated Risk ◽  
Evidence Based ◽  
Executive Summary ◽  
Specific Patient ◽  
Immunomodulatory Agents ◽  
Immunization Rates ◽  
Immune Mediated ◽  
Multidisciplinary Group

The use of immunosuppressive therapies for immune-mediated disease is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases, and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive and immunomodulatory agents.

scholarly journals Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies—Executive Summary

2019 ◽  
Vol 2 (4) ◽  
pp. 149-152 ◽  
Author(s):  
Kim A Papp ◽  
Boulos Haraoui ◽  
Deepali Kumar ◽  
John K Marshall ◽  
Robert Bissonnette ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Patient Population ◽  
Immunosuppressive Agents ◽  
Elevated Risk ◽  
Evidence Based ◽  
Executive Summary ◽  
Specific Patient ◽  
Immunization Rates ◽  
Immune Mediated ◽  
Multidisciplinary Group

Abstract The use of immunosuppressive therapies for immune-mediated disease (IMD) is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive agents.

scholarly journals Severe illicit gamma-hydroxybutyric acid withdrawal in a pregnant woman: what to do?

2019 ◽  
Vol 12 (12) ◽  
pp. e230997 ◽  
Author(s):  
JC van Mechelen ◽  
BAG Dijkstra ◽  
ACM Vergouwen
Keyword(s):  
Emergency Department ◽  
Case Report ◽  
Pregnant Woman ◽  
Withdrawal Symptom ◽  
Patient Population ◽  
Treatment Options ◽  
Sodium Oxybate ◽  
Evidence Based ◽  
Hydroxybutyric Acid ◽  
Specific Patient

This case report presents the case of a 29 weeks pregnant woman in her late twenties who was seen at the emergency department of a hospital with a seizure of unknown cause. By anamnesis and hetero-anamnesis the use of illicit gamma-hydroxybutyric acid (GHB) was revealed. Examination showed dilated pupils, sweating, tremor, tachycardia and bradyphrenic thinking. Subsequently, the seizure was indicated as a severe illicit GHB withdrawal symptom. Thereafter, treatment had to be decided on in the absence of evidence-based and practiced-based guidelines and treatment options for this specific patient population. Initially diazepam was started, which was later on substituted by sodium oxybate. Despite the critical professional situation the patient gave birth to a healthy daughter after 37 weeks of pregnancy.

Craniectomy with microvascular flap reconstruction in a patient taking infliximab for vasculitis

2020 ◽  
Vol 13 (12) ◽  
pp. e238614
Author(s):  
Ogonna N Nnamani Silva ◽  
Audrey B Nguyen ◽  
William Y Hoffman
Keyword(s):  
Diabetes Mellitus ◽  
Latissimus Dorsi ◽  
Perioperative Management ◽  
Large Cell ◽  
Evidence Based ◽  
Flap Reconstruction ◽  
Biologic Drugs ◽  
Temporal Arteries ◽  
Immune Mediated ◽  
Microvascular Flap

For patients whose vasculitis is managed with biologic medications, no reports or evidence-based guidance exists regarding the perioperative management of microvascular flaps. We present a case of a 78-year-old patient with Takayasu’s arteritis (TA) and diabetes mellitus who was taking infliximab and underwent wide local excision of squamous cell carcinoma, craniectomy and reconstruction with a latissimus dorsi flap. TA, an immune-mediated large cell vasculitis characterised by granuloma formation, tends to affect larger vessels and aortic branches. The typical localisation of this condition raises concerns about potentially compromised pedicle and recipient vessels (ie, superficial temporal arteries), which could hinder postoperative flap success. Discontinuation of infliximab 4 weeks before surgery and resumption 6 weeks after led to favourable results. This case addresses the gap in the literature concerning stopping and restarting biologic drugs in the perioperative setting and documents a successful course of a microvascular procedure in a patient with vasculitis.

Facile syringe filter-enabled bacteria separation, enrichment, and buffer exchange for clinical isolation-free digital detection and characterization of bacterial pathogens in urine

The Analyst ◽  
2021 ◽  
Author(s):  
Pengfei Zhang ◽  
Aniruddha Kaushik ◽  
Kathleen E Mach ◽  
Kuangwen Hsieh ◽  
Joseph C. Liao ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Antibiotic Therapy ◽  
Broad Spectrum ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Evidence Based ◽  
Pathogen Identification ◽  
Accelerated Methods ◽  
Syringe Filter

The development of accelerated methods for pathogen identification (ID) and antimicrobial susceptibility testing (AST) for infectious diseases is necessary to facilitate evidence-based antibiotic therapy and reduce clinical overreliance on broad-spectrum...

scholarly journals Publication by association: how the COVID-19 pandemic has shown relationships between authors and editorial board members in the field of infectious diseases

2021 ◽  
pp. bmjebm-2021-111670
Author(s):  
Clara Locher ◽  
David Moher ◽  
Ioana Alina Cristea ◽  
Florian Naudet
Keyword(s):  
Infectious Diseases ◽  
Evidence Based Medicine ◽  
Medical Community ◽  
Board Members ◽  
Evidence Based ◽  
Ripple Effect ◽  
New Type ◽  
Based Medicine

During the COVID-19 pandemic, the rush to scientific and political judgements on the merits of hydroxychloroquine was fuelled by dubious papers which may have been published because the authors were not independent from the practices of the journals in which they appeared. This example leads us to consider a new type of illegitimate publishing entity, ‘self-promotion journals’ which could be deployed to serve the instrumentalisation of productivity-based metrics, with a ripple effect on decisions about promotion, tenure and grant funding, but also on the quality of manuscripts that are disseminated to the medical community and form the foundation of evidence-based medicine.

Sign in / Sign up

Export Citation Format

Share Document